Chair: Emilie Le Rhun

OS01.1 Women's perspective
Ghazaleh Tabatabai, Germany
Estela Pineda, Spain
Susan Short, United Kingdom
Karin Piil, Denmark
Julia Furtner-Srajer, Austria

OS01.2 Disparity of care
Bozena Kaminska, Poland
Tomas Kazda, Czech Republic
Pieter Wesseling, Netherlands
Simone Niclou, Luxembourg
Maciej Mrugala, United States

Chairs: Elizabeth Cohen-Moyal, Anthony Chalmers

WS01.1 Optimzing radiotherapy using Nanoparticles
Karl Butterworth, United Kingdom

WS01.2 Intrinsic radioresistance and FGFR pathway
Elizabeth Cohen-Moyal, France

WS01.3 Aberrant DNA repair as a therapeutic target in glioblastoma
Petra Hamerlik, Denmark

Chairs: Mihaela Lorger, Michael Platten

KS01.1 Acquired immune system (T cells)
Burkhard Becher, Switzerland

KS01.2 Exploring and Therapeutically Exploiting the Brain Tumour Microenvironment
Johanna Joyce, Switzerland

KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion
Yu-Chan Chih, Germany

KS01.4.A NK cells as key orchestrators in mediating the anti-tumour response to immune checkpoint blockade in melanoma brain metastases
Christopher Fife, United Kingdom

KS01.5.A Allergic airway inflammation impacts tumor take and delays experimental glioblastoma progression
Aurélie Poli, Luxembourg

KS01.6.A Comparative analysis of the immune compartment in human glioblastoma and IDH-mutant WHO grade 4 astrocytoma reveals profound differences in microglia phenotypes
Roman Sankowski, Germany

Chairs: Oliver Hanemann, Matthias Preusser

OS02.1 Impact of tumor plasticity on experimental therapies for brain metastases
Manuel Valiente, Spain

OS02.2 Tumor plasticity from a neurosurgical perspective
Colin Watts, United Kingdom

OS02.3 Your viewpoint on the impact of tumor heterogeneity on experimental therapies
Wolfgang Wick, Germany

OS02.4.A Molecular characterization of adult cerebellar glioblastomas identifies distinct prognosis subgroups
Thiébaud Picart, France

OS02.5.A Glioblastoma Metabolic Symbiosis : When Lactate Takes The Lead.
Thomas Daubon, France

OS02.6.A The TeloDIAG : How telomeric parameters can help in glioma rapid diagnosis and liquid biopsies approaches
Delphine Poncet, France

Chairs: Elizabeth Cohen-Moyal, Anthony Chalmers

OS03.1 Carbon ion therapy for brain tumours in theory and in practice
Stephanie Combs, Germany

OS03.2 Proton beam therapy for adult central nervous system tumours: pros and cons
Gillian Whitfield, United Kingdom

OS03.3.A Characterization of long-term metabolic changes of irradiated brain metastases using serial dynamic FET PET imaging
Norbert Galldiks, Germany

OS03.4.A Irradiation of the subventricular and subgranular zone and overall survival in high-grade glioma patients
Danique Bruil, Netherlands

OS03.5.A Corelation between longitudinal t2 MRI radiomic primary texture feature values and radiation dose in non-tumoral regions of the brain in paediatric brain tumours
Priyanka Sakhavalkar, United Kingdom

Chairs: Roberta Rudà, Martin van den Bent

ME01.1 Medulloblastoma: a multicenter trial in adult patients
Peter Hau, Germany

ME01.2 EURACAN and CNS tumors: background of the effort
Ahmed Idbaih, France

ME01.3 NTRK fusions and glioma
Evangelia Razis, Greece

Chairs: Gelareh Zadeh, Asgeir Jakola

ME02.1 Continous dynamic mapping for removal of brain tumors in eloquent brain regions
Kathleen Seidel, Switzerland

ME02.2 Laser ablation - Indications in Neuro-oncology
Mark ter Laan, Netherlands

ME02.3 Integrated Classification of Meningiomas
Gelareh Zadeh, Canada

Chairs: Marjolein Geurts, Simona Gaito

WS02.1 You cannot not communicate
Eva Masel, Austria

WS02.2 Palliative care and end-of-life management in brain tumors
Andrea Pace, Italy

Chairs: Simone Niclou, Pim French

PL02.1 Cancer dependency maps
Mathew Garnett, United Kingdom

PL02.2 Exceptional Responders: Inferences from N of 1 Experiments
David Wheeler, United States

PL02.3.A Phenotypic heterogeneity and plasticity as resistance mechanisms in Glioblastoma
Anna Golebiewska, Luxembourg

PL02.4.A Chromosome 1p19q codeletion frequency, but not survival, varies according to the IDH mutation subtypes: analysis of 1050 IDH-mutated diffuse gliomas.
Alberto Picca, France

PL02.5.A The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDHwildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study.
Giuseppe Lombardi, Italy

Chairs: Antonella Castellano, Patrick Roth

JS02.1 Treatment Monitoring in Brain tumors: New Insights by Amino Acid PET, „ImmunoPET“ and PET Radiomics?
Norbert Galldiks, Germany

JS02.2 TSPO – a new tracer for imaging glioma and microglia
Jörg Tonn, Germany

JS02.3 Radiolabeld compounds as theranostics of brain tumors
Tatjana Traub-Weidinger, Austria

Chairs: Susan Chang, Wolfgang Wick

JS03.1 Evidence based: 6 cycles of adjuvant temozomide suffices in glioblastoma
Carmen Balanà Quintero, Spain

JS03.2 IDH inhibitors: early signs of activity?
Ingo Mellinghoff, United States

JS03.3 Detection and discrimination of intracranial tumors by blood
Farshad Nassiri, Canada

JS03.4 Synaptic communication in brain tumours
Varun Venkataramani, Germany

Chairs: Marike Broekman, Martin van den Bent

JS04.1 When and why to perform repeated surgery for progressive LGG
Lorenzo Bello, Italy

JS04.2 Systemic therapies for intracranial metastasis, what are the options and when to refer for local therapy?
Anna Berghoff, Austria

JS04.3 Neurosurgical and radiosurgical decision making in patients with brain metastases in the era of personalized medicine
Philippe Métellus, France

JS04.4 Oncological treatment in progressive LGG following surgery - or should all be treated upfront?
Martin van den Bent, Netherlands